非布司他是否可以根治痛风？

Febuxostat (febuxostat, feburic) is a selective inhibitor of non-purine xanthine oxidase/xanthine dehydrogenase. In June 2013, China's State Food and Drug Administration approved febuxostat (febuxostat, feburic) for marketing in China.

  A clinical trial included the clinical data of 40 gout patients, and all case data were consecutive and complete. According to the medication status of the patients, they were divided into febuxostat (febuxostat, feburic) group and allopurinol group, with 20 cases in each group. Patients in the febuxostat (febuxostat, feburic) group took febuxostat (febuxostat, feburic) tablets orally, and the allopurinol group took orally allopurinol. The serum uric acid levels, gout symptom improvement, post-treatment clinical effects and adverse reactions of the two groups of patients before and after treatment were observed. Results Comparison of serum uric acid levels between the two groups of patients before treatment.

After treatment, the serum uric acid level of patients in the febuxostat group [(372.55±90.80) μmol/L] was lower than that of the allopurinol group [(413.25±141.31) μmol/L], and the difference was statistically significant (P<0.05). The serum uric acid compliance rate (55.0%) and symptom improvement rate (95.0%) of patients in the febuxostat group were higher than those in the allopurinol group (35.0%, 85.0%). The incidence of adverse reactions in the febuxostat (febuxostat, feburic) group (20.0%) was lower than that in the allopurinol group (30.0%). The conclusion shows that febuxostat is more effective and safer than allopurinol in treating gout and is worthy of clinical promotion and application.

The effect of febuxostat in treating gout is remarkable. Why should patients ask their medical companions whether febuxostat can cure gout?

The Medical Companion Brigade learned that febuxostat cannot cure gout. It can inhibit the synthesis of uric acid in our body and can only control the onset of gout.